Status:
COMPLETED
Extension Study of Semapimod 60 mg IV x 3 Days
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Crohn's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Study CNI-1493-CD06 is an open, single-arm extension studies to CD03 and CD05. CDAI is the only efficacy measure assessed in this study. The safety of multiple courses of semapimod is to be determined...
Eligibility Criteria
Inclusion
- The study was open to patients who had satisfactorily completed either study CNI-1493-CD-03 or CNI-1493-CD-05. Initial entry criteria were:
- Patients who satisfactorily completed either study CNI-1493-CD-03 or CD-05 were eligible for participation in this study. Satisfactory completion was defined as follows:
- The patient completed 5 treatment courses in the previous trial.
- The patient had responded to treatment, as defined by a decrease in CDAI of at least 70 points from original baseline (prior to treatment on study CD-02 or CD-04) at the last assessment for study CD-03 or CD-05, respectively. The decrease had to be attributable to semapimod treatment. Thus, patients whose response was attributable to other anti-Crohn's disease therapy are not to be included.
- The patient had no adverse event \>grade 2 felt to be probably or definitely related to study medication.
- The patient did not meet any discontinuation criterion in previous trial.
- Patients had to sign informed consent specifically for this study, in addition to the consents for the previous studies, CNI-1493-CD-02 or CD-03, and CNI-1493-CD-04 or CD-05.
- Patients could not take any other investigational therapies during the course of this study.
- Men and women of childbearing potential had to be using a barrier method (diaphragm or condom) of contraception and continue doing so for at least 3 months after last study medication. It was strongly recommended that two forms be used.
- Patients had to be able to adhere to the study visit schedule and/or protocol requirements.
Exclusion
- Could not have met any of the exclusion criteria for the CD02, 03, 04 or 05 studies.
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00741910
Start Date
July 1 2003
End Date
June 1 2006
Last Update
November 18 2023
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60611
2
Long Island Clinical Research Associates
Great Neck, New York, United States, 11021
3
Asher Kornbluth, MD
New York, New York, United States, 10128
4
Benjamin Franklin University
Berlin, Germany